Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have earned an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.

Brokerages have set a twelve-month consensus price objective of $31.00 for the company, according to Zacks. Zacks has also given Rhythm Pharmaceuticals an industry rank of 109 out of 265 based on the ratings given to related companies.

A number of research firms have issued reports on RYTM. Morgan Stanley began coverage on Rhythm Pharmaceuticals in a research report on Monday. They issued an “equal weight” rating and a $23.00 target price for the company. Needham & Company LLC began coverage on Rhythm Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $32.00 target price for the company. Bank of America Corporation began coverage on Rhythm Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a $30.00 target price for the company. Finally, Cowen and Company began coverage on Rhythm Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $40.00 target price for the company.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Set $31.00 Price Target for Rhythm Pharmaceuticals, Inc. (RYTM)” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/31/zacks-analysts-set-31-00-price-target-for-rhythm-pharmaceuticals-inc-rytm.html.

Rhythm Pharmaceuticals (NASDAQ:RYTM) traded up 1.92% on Tuesday, hitting $24.89. The company had a trading volume of 56,757 shares. The stock has a 50 day moving average of $24.24 and a 200-day moving average of $24.24. The stock’s market capitalization is $648.98 million. Rhythm Pharmaceuticals has a one year low of $21.38 and a one year high of $33.81.

In other Rhythm Pharmaceuticals news, major shareholder S.A. Ipsen acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 10th. The stock was bought at an average price of $17.00 per share, with a total value of $340,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bros. Advisors Lp Baker acquired 885,000 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The shares were acquired at an average cost of $17.00 per share, with a total value of $15,045,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 1,285,000 shares of company stock valued at $21,845,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.